Subtype
Genitourinary System Carcinoma
CI-CAN-00000925Explore in graph →
1,498 active trials44 approved drugs143 evidence items
- NCIt
- C164141
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000925Explore in graph →
Clinical trials
4,916 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (758)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06250244 | 177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 12 | Peking Union Medical College HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT05867303 | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | unknown | Phase 1 | 48 | RemeGen Co., Ltd.INDUSTRY | 2 | Aug 16, 2024 | clinicaltrials |
| NCT06237491 | The Safety and Dosimetry Study of 177Lu-LNC1003 Injection | unknown | Phase 1 | 12 | Yantai LNC Biotechnology Singapore PTE. LTD.INDUSTRY | 0 | Jul 24, 2024 | clinicaltrials |
| NCT05354102 | A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 | unknown | Phase 1 | 11 | Biomica Ltd.INDUSTRY | 1 | May 7, 2024 | clinicaltrials |
| NCT05458544 | [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application(LUCIDA) | unknown | Phase 1 / Phase 2 | 26 | FutureChemINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT06344715 | Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC. | unknown | Phase 1 | 78 | SL VAXiGENINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06241235 | Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma | unknown | Phase 1 / Phase 2 | 48 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT04903873 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 110 | EutilexINDUSTRY | 2 | Mar 15, 2024 | clinicaltrials |
| NCT03549715 | NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma(NEMIO) | unknown | Phase 1 / Phase 2 | 121 | Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05472857 | Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression | unknown | Phase 1 | 30 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT02730923 | Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)(VICTORIA) | unknown | Phase 1 / Phase 2 | 72 | Centre Leon BerardOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05787535 | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | unknown | Phase 1 | 17 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06221774 | Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors | unknown | Phase 1 / Phase 2 | 42 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06182735 | CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma | unknown | Phase 1 | 9 | Fudan UniversityOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT02935205 | Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 38 | Mamta ParikhOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04097002 | First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. | unknown | Phase 1 / Phase 2 | 24 | Orca Therapeutics B.V.INDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT05259319 | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)(IMMUNOs-SBRT) | unknown | Phase 1 | 92 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06049030 | A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma | unknown | Phase 1 | 190 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 26, 2023 | clinicaltrials |
| NCT06055348 | SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer | unknown | Phase 1 / Phase 2 | 112 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 0 | Sep 26, 2023 | clinicaltrials |
| NCT05420519 | Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer | unknown | Phase 1 | 24 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05420545 | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | unknown | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05468190 | A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T | unknown | Phase 1 | 48 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT04678102 | Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)(CREATIVE) | unknown | Phase 1 | 36 | Seoul National University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05607693 | A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects | unknown | Phase 1 | 52 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT05843305 | A Study of BPI-452080 in Subjects With Solid Tumors | unknown | Phase 1 | 87 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT05798455 | Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Tabriz University of Medical SciencesOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05533203 | Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC) | unknown | Phase 1 | 24 | Shanghai Humantech Biotechnology Co. LtdINDUSTRY | 1 | Jan 23, 2023 | clinicaltrials |
| NCT04262427 | The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma(CAPER) | unknown | Phase 1 / Phase 2 | 21 | The Christie NHS Foundation TrustOTHER | 1 | Aug 23, 2022 | clinicaltrials |
| NCT04982146 | Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei | unknown | Phase 1 | 10 | Maimónides Biomedical Research Institute of CórdobaOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT03780075 | Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 | 50 | Peking Union Medical College HospitalOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT03542669 | Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer | unknown | Phase 1 | 9 | Peking University People's HospitalOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05262413 | A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC) | unknown | Phase 1 / Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 2, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT04603846 | A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma | unknown | Phase 1 | 20 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Jan 24, 2022 | clinicaltrials |
| NCT03715985 | Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)(NeoPepVac) | unknown | Phase 1 / Phase 2 | 12 | Herlev HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04620954 | Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin(ORION-02) | unknown | Phase 1 / Phase 2 | 31 | National Cancer Centre, SingaporeOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT04443296 | Study of Tumor Infiltrating Lymphocytes Following CCRT in the Treatment of Patients With Cervical Carcinoma(TIL-Cx) | unknown | Phase 1 | 10 | Sun Yat-sen UniversityOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT05086666 | A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547 | unknown | Phase 1 / Phase 2 | 108 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Oct 21, 2021 | clinicaltrials |
| NCT02497599 | Intraoperative Dual-modality Imaging in Renal Cell Carcinoma | unknown | Phase 1 | 30 | Radboud University Medical CenterOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT05013268 | Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma(TiTanec) | unknown | Phase 1 | 15 | Ruijin HospitalOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04871334 | Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma | unknown | Phase 1 | 76 | Shandong TheraWisdom Biopharma Co., Ltd.INDUSTRY | 1 | Jul 23, 2021 | clinicaltrials |
| NCT02785250 | Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 85 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Jun 18, 2021 | clinicaltrials |
| NCT04839055 | The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC(CoA-CRPC) | unknown | Phase 1 / Phase 2 | 50 | Jiangnan UniversityOTHER | 1 | Apr 9, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Dec 11, 2024source: clinicaltrials